Search

Your search keyword '"Pulendran, Bali"' showing total 269 results

Search Constraints

Start Over You searched for: Author "Pulendran, Bali" Remove constraint Author: "Pulendran, Bali" Database Unpaywall Remove constraint Database: Unpaywall
269 results on '"Pulendran, Bali"'

Search Results

1. Impaired innate and adaptive immune responses to BNT162b2 SARS-CoV-2 vaccination in systemic lupus erythematosus

2. Corrigendum to “Phenotypes of disease severity in a cohort of hospitalized COVID-19 patients: results from the IMPACC study” [eBioMedicine 83 (2022) 104208]

3. Integrated longitudinal multi-omics study identifies immune programs associated with COVID-19 severity and mortality in 1152 hospitalized participants

4. Author Correction: A ferritin-based COVID-19 nanoparticle vaccine that elicits robust, durable, broad-spectrum neutralizing antisera in non-human primates

5. Multi-omics analysis of mucosal and systemic immunity to SARS-CoV-2 after birth

7. List of Contributors

8. Intradermal but not intramuscular modified vaccinia Ankara immunizations protect against intravaginal tier2 simian-human immunodeficiency virus challenges in female macaques

9. Integrated Organ Immunity: Antigen-specific CD4-T cell-derived IFN-γ induced by BCG imprints prolonged lung innate resistance against respiratory viruses

10. Saponin Nanoparticle Adjuvants Incorporating Toll-Like Receptor Agonists Improve Vaccine Immunomodulation

11. Addendum: Systems vaccinology of the BNT162b2 mRNA vaccine in humans

12. Broadly neutralizing antibodies against sarbecoviruses generated by immunization of macaques with an AS03-adjuvanted COVID-19 vaccine

15. Disease Tolerance Acquired Through Repeated Plasmodium Infection Involves Epigenetic Reprogramming of Innate Immune Cells

16. A ferritin-based COVID-19 nanoparticle vaccine that elicits robust, durable, broad-spectrum neutralizing antisera in non-human primates

17. Progress in vaccine development for infectious diseases—a Keystone Symposia report

18. Durability of immune responses to the booster mRNA vaccination against COVID-19

19. Robust T cell responses to Pfizer/BioNTech vaccine compared to infection and evidence of attenuated peripheral CD8+ T cell responses due to COVID-19

20. Systems biological assessment of the temporal dynamics of immunity to a viral infection in the first weeks and months of life

21. A TLR7-nanoparticle adjuvant promotes a broad immune response against heterologous strains of influenza and SARS-CoV-2

22. Extremely potent pan-sarbecovirus neutralizing antibodies generated by immunization of macaques with an AS03-adjuvanted monovalent subunit vaccine against SARS-CoV-2

23. Disease Tolerance of Malaria Involves Epigenetic Reprogramming of Innate Immune Cells

24. Robust T Cell Responses to the Pfizer/BioNTech Vaccine Compared to Infection and Evidence of Attenuated CD8 T Cell Responses Due to COVID-19

25. Ablation of Adar1 in myeloid cells imprints a global antiviral state in the lung and heightens early immunity against SARS-CoV-2

26. SREBP signaling is essential for effective B cell responses

27. A ferritin-based COVID-19 nanoparticle vaccine that elicits robust, durable, broad-spectrum neutralizing antisera in non-human primates

28. Author Correction: The persistence of memory: defining, engineering, and measuring vaccine durability

30. Durability of immune responses to the booster mRNA vaccination against COVID-19

31. The persistence of memory: defining, engineering, and measuring vaccine durability

32. Early immune markers of clinical, virological, and immunological outcomes in patients with COVID-19: a multi-omics study

34. Phenotypes of disease severity in a cohort of hospitalized COVID-19 patients: Results from the IMPACC study

35. Durable protection against the SARS-CoV-2 Omicron variant is induced by an adjuvanted subunit vaccine

36. Author response: Early immune markers of clinical, virological, and immunological outcomes in patients with COVID-19: a multi-omics study

37. Distinct sensitivities to SARS-CoV-2 variants in vaccinated humans and mice

39. Adjuvanting a subunit SARS-CoV-2 vaccine with clinically relevant adjuvants induces durable protection in mice

40. Durable protection against SARS-CoV-2 Omicron induced by an adjuvanted subunit vaccine

41. Mechanisms of innate and adaptive immunity to the Pfizer-BioNTech BNT162b2 vaccine

42. Early non-neutralizing, afucosylated antibody responses are associated with COVID-19 severity

43. Antibodies elicited by SARS-CoV-2 infection or mRNA vaccines have reduced neutralizing activity against Beta and Omicron pseudoviruses

44. Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination

45. Distinct sensitivities to SARS-CoV-2 variants in vaccinated humans and mice

46. Early immune responses have long-term associations with clinical, virologic, and immunologic outcomes in patients with COVID-19

50. Safety, immunogenicity, and protection provided by unadjuvanted and adjuvanted formulations of a recombinant plant-derived virus-like particle vaccine candidate for COVID-19 in nonhuman primates

Catalog

Books, media, physical & digital resources